Tim Chiang now sees a bigger per share value for ARDX’s tenapanor in the IBS-C market.
Oren Livnat expects MannKind’s inhaled insulin’s new label will be a real game-changer.
One analyst likes Nvidia’s stellar fall video game slate; top analyst cheers Intel’s improved Notebook sales.
Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.
Apple’s Soaring ASPs Are Enticing Apple Inc. (NASDAQ:AAPL) is about to reap the rewards of …
Analyst sees higher ad revenue per daily active user growth ahead for Snap and attractive valuation.
Analyst nearly doubles price target between Gocovri pricing and better prospects in Multiple Sclerosis arena.
Analyst bumps up price target on QDEL on back of “sweetened” deal to acquire Alere’s BNP Assay segment.
Analyst lifts price target on Oncolytics with new clarity from the FDA on Reolysin’s path forward to approval.
Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.